506820 Stock Overview
A biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
AstraZeneca Pharma India Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹6,336.90 |
| 52 Week High | ₹8,139.85 |
| 52 Week Low | ₹4,050.15 |
| Beta | 0.29 |
| 11 Month Change | -11.51% |
| 3 Month Change | -7.63% |
| 1 Year Change | 36.26% |
| 33 Year Change | 99.35% |
| 5 Year Change | 139.52% |
| Change since IPO | 10,825.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| 506820 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -6.4% | 0.5% | 0.5% |
| 1Y | 36.3% | 42.5% | 27.5% |
Return vs Industry: 506820 underperformed the Indian Pharmaceuticals industry which returned 42.5% over the past year.
Return vs Market: 506820 exceeded the Indian Market which returned 27.5% over the past year.
Price Volatility
| 506820 volatility | |
|---|---|
| 506820 Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 506820 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 506820's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 800 | Sanjeev Panchal | www.astrazeneca.in |
AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease, renal, and metabolism medicines under the CRESTOR, Forxiga, BRILINTA, Xigduo, and Seloken XL brand names; oncology medicines under the TAGRISSO, CALQUENCE, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes and immunology diseases.
AstraZeneca Pharma India Limited Fundamentals Summary
| 506820 fundamental statistics | |
|---|---|
| Market cap | ₹158.42b |
| Earnings (TTM) | ₹819.20m |
| Revenue (TTM) | ₹14.85b |
193.4x
P/E Ratio10.7x
P/S RatioIs 506820 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 506820 income statement (TTM) | |
|---|---|
| Revenue | ₹14.85b |
| Cost of Revenue | ₹8.24b |
| Gross Profit | ₹6.60b |
| Other Expenses | ₹5.78b |
| Earnings | ₹819.20m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 32.77 |
| Gross Margin | 44.46% |
| Net Profit Margin | 5.52% |
| Debt/Equity Ratio | 0% |
How did 506820 perform over the long term?
See historical performance and comparison